

SCREENING

The variables related to this form are located in the LADS.PRERAND data file.

Complete for all eligible patients who are placed on run-in and fax (1-800-793-8524) this form to the CSCC. Chapter 2 of the PEACE Manual of Operations contains details for completing this form.

A. IDENTIFYING INFORMATION

- | | |
|--|---|
| 1. PEACE Center: deleted _____ | 3. Patient Initials: deleted _____ |
| | Last First |
| 2. PEACE I.D.: _____ | 4. Today's Date: deleted _____ |
| New variable generated - new random ID [NEW_ID] | Mo Day Yr |

B. INCLUSION CRITERIA (Indicate Yes or No for 1b, 2, 3a, 3b and 3c)

- | | | |
|--|------------|-----------|
| | YES | NO |
| 1. a) Birth Date _____/_____/_____ | | |
| Mo Day Yr | | |
| Recoded - age at randomization [AGE] | | |
| b) Age at randomization \geq 50 years deleted | (1) | (2) |
| 2. Left ventricular ejection fraction (LVEF) > 40% or a qualitatively normal echo or angiogram of the LV in the absence of a wall motion abnormality, within the previous 18 months deleted | (1) | (2) |
| 3. a) Myocardial Infarction at least 3 months prior to randomization deleted | (1) | (2) |
| b) CABG or PTCA at least 3 months prior to randomization deleted | (1) | (2) |
| c) Coronary angiogram indicating at least one coronary artery obstruction = 50% deleted | (1) | (2) |

Questions 1b, 2, and 3a or 3b or 3c MUST be marked YES to permit study participation.

- | | | |
|----------------------------|--------------------------------|---|
| 4. Race: deleted | White, not Hispanic (1) | American Indian or Alaska Native (4) |
| | Black, not Hispanic (2) | Asian or Pacific Islander (5) |
| | Hispanic (3) | Other (6) |
| 5. Gender: [GENDER] | | Female (1) Male (2) |

C. EXCLUSION CRITERIA

After first YES, stop and go to Section D.

- | | | |
|--|------------|-----------|
| | YES | NO |
| 1. Currently prescribed an ACE inhibitor and unable or unwilling to stop deleted | | (1) |
| 2. Contraindication to the use of an ACE inhibitor deleted | (1) | (2) |
| 3. Current clinical requirements for the use of an ACE inhibitor deleted | (1) | (2) |
| 4. Current use of angiotensin II receptor antagonist which cannot be discontinued deleted | (1) | (2) |
| 5. Hospitalization for unstable angina within the last 2 months deleted | (1) | (2) |
| 6. Valvular heart disease likely to require surgery deleted | (1) | (2) |
| 7. Coronary artery bypass surgery (CABG) within the last 3 months deleted | (1) | (2) |
| 8. Percutaneous transluminal coronary angioplasty (PTCA) within the last 3 months deleted | (1) | (2) |
| 9. Plans for elective CABG or PTCA deleted | (1) | (2) |
| 10. Serum creatinine > 2.0 mg/dL or 177 μ mol/L (renal failure) deleted | (1) | (2) |
| 11. Serum potassium \geq 5.5 mEq/L or 5.5 mmol/L deleted | (1) | (2) |
| 12. Other concurrent medical conditions likely to limit 5-year survival deleted | (1) | (2) |
| 13. Psychosocial conditions not conducive to adherence deleted | (1) | (2) |
| 14. Inability or unwillingness to provide written informed consent deleted | (1) | (2) |
| 15. Woman of childbearing potential not using adequate contraception deleted | (1) | (2) |
| 16. Current use of non-FDA or non-HPB approved medication in a research trial deleted | (1) | (2) |

If the patient will continue the screening process, schedule the Pre-randomization Visit.

D. _____ ~~_____~~ ~~_____~~ ~~_____~~ ~~_____~~ ~~_____~~ ~~_____~~
Signature of individual completing this form *Mo Day Yr* *Certification No.*